Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease
Colin Dingwall
Colin Dingwall
Published November 1, 2001
Citation Information: J Clin Invest. 2001;108(9):1243-1246. https://doi.org/10.1172/JCI14402.
View: Text | PDF
Spotlight

Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease

  • Text
  • PDF
Abstract

Authors

Colin Dingwall

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
APP processing pathway and and domain organization of β-secretase. (a) A...
APP processing pathway and and domain organization of β-secretase. (a) A schematic representation of the sequential cleavages of APP at the β- and γ- sites to generate β-amyloid. APP and β-secretase are both integral membrane proteins with type 1 orientation, γ-secretase is probably PS 1, a protein with eight TM domains (not shown). Recent data indicates that these three proteins assemble in conjunction with Nicastrin, a protein which interacts with PS1, in cholesterol rich microdomains in cellular membranes. (b) The amyloid domain of APP showing the mutations which are associated with early onset familial forms of AD, highlighting those which occur at the secretase cleavage sites. The beginning of the TM domain is shown. (c) Domain organization of β-secretase. The protein has a cleaved signal peptide, a prodomain and a catalytic domain in which the catalytic aspartic residues are located. The catalytic domain shows the 3 di-sulfide bridges characteristic of the pepsin family of aspartic proteinases and is glycosylated at 4 sites. The cytoplasmic tail contains a di-leucine endosomal retreival signal, cysteine residues which are palmitoylated and phosphorylation sites. The homolog, Asp1 (DRAP, BACE2) shows the same overall structural organization.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts